argenx SE ARGX 深 沪
已收盘 05-15 16:00:00 美东时间
799.32
-22.810
-2.77%
华盛通- 最 高820.325
- 今 开819.815
- 成交量 32.64万股
- 最 低 797.77
- 昨 收 822.13
- 总市值 497.08亿
- 52周最高 934.6199
- 市盈率 静 40.72
- 换手率 0.52%
- 52周最低 510.055
- 委 比 65.37%
- 总股本 6218.78万
- 历史最高 934.6199
- 量 比 0.92
- 振 幅 2.74%
- 历史最低 19.00
- 每 手 1
- 风险率 111.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Evercore ISI Group Maintains Outperform on argenx, Raises Price Target to $1059
Evercore ISI Group analyst Gavin Clark-Gartner maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target from $1007 to $1059.
05-16 01:24
Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease
Argenx shares rise after FDA expands VYVGART approval to all adult gMG patients, widening the drug's market opportunity.
05-12 01:37
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1260
Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1247 to $1260.
05-08 21:11
argenx Q1 EPS $5.52 Beats $5.42 Estimate, Sales $1.313B Miss $1.314B Estimate
argenx (NASDAQ:ARGX) reported quarterly earnings of $5.52 per share which beat the analyst consensus estimate of $5.42 by 1.85 percent. This is a 113.95 percent increase over earnings of $2.58 per share from the same
05-07 13:17
Argenx Appoints Karen Massey CEO, Tim Van Hauwermeiren Board Chairperson
argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of people suffering from severe autoimmune diseases, today announced the results of the Annual General Meeting of
05-07 04:04
Why Is Viridian Therapeutics Stock Sinking Monday?
Viridian shares fall after Amgen TEPEZZA Phase 3 data shows stronger efficacy, raising concerns over elegrobart's position in the TED market.
04-07 01:41
美股大行评级 | 摩根大通上调霸王茶姬至"超配"，目标价上调至16美元；康尼格拉食品遭高盛、瑞银等7家机构下调目标价
今日重点评级关注：Leerink Partners：维持Camp4 Therapeutics"跑赢大市"评级，目标价从8美元升至9美元；韦德布什：维持Arcus Biosciences"跑赢大市"评级，目标价从37美元升至41美元
04-06 16:27
Oppenheimer Maintains Outperform on argenx, Lowers Price Target to $1014
Oppenheimer analyst Leland Gershell maintains argenx (NASDAQ:ARGX) with a Outperform and lowers the price target from $1060 to $1014.
04-03 00:22
Why Is Viridian Therapeutics Stock Falling Monday?
Viridian (VRDN) shares plunge 38% premarket despite positive Phase 3 TED trial data. Analysts weigh in on elegrobart's market viability.
03-30 22:01
